Screening the blood supply for West Nile virus RNA by nucleic acid amplification testing.

BACKGROUND The use of nucleic acid amplification tests of "minipools" of 16 samples to screen blood donors for West Nile virus RNA began in July 2003. We report the yield and characteristics of positive donations and the incremental yield and safety of nucleic acid amplification tests of individual donations. METHODS Reactive minipools were analyzed to identify the individual reactive donations. For the regions with the highest yield on minipool testing, retrospective nucleic acid amplification testing was performed on individual donations that were negative on minipool testing. Reactive donations were confirmed by alternative nucleic acid amplification tests and IgM and IgG tests, and donors were followed to document seroconversion. RESULTS From July 1 through October 31, 2003, 677,603 donations were prospectively screened for West Nile virus by minipool testing, yielding 183 confirmed viremic donations (0.027 percent, or 1 in 3703 donations). Retrospective individual testing of 23,088 donations from high-prevalence regions that were negative on minipool testing yielded 30 additional units with a low level of viremia, with 14 additional viremic units detected by prospective testing of individual donations late in the 2003 transmission season. Of all the viremic units detected, 5 percent were detected only by individual testing and were negative for IgM antibody, 29 percent were detected by individual testing after IgM seroconversion, and 66 percent were detected by minipool testing. West Nile virus infection was confirmed in both recipients of IgM-negative units that were reactive on individual testing, whereas neither recipient of antibody-positive blood components that were reactive on individual testing was infected. In 2004, prospective testing of individual donations in regions that yielded donations that were reactive on minipool testing resulted in a 32 percent incremental yield of units with a low level of viremia that would have been missed by minipool testing. CONCLUSIONS Although nucleic acid amplification testing of minipools of blood donations prevented hundreds of cases of West Nile virus infection in 2003, it failed to detect units with a low level of viremia, some of which were antibody-negative and infectious. These data support the use of targeted nucleic acid amplification testing of individual donations in high-prevalence regions, a strategy that was implemented successfully in 2004.

[1]  S. Glynn,et al.  A new strategy for estimating risks of transfusion‐transmitted viral infections based on rates of detection of recently infected donors , 2005, Transfusion.

[2]  J. Epstein Insights on donor screening for West Nile virus , 2005, Transfusion.

[3]  S. Glynn,et al.  The 2003 West Nile virus United States epidemic: the America's Blood Centers experience , 2005, Transfusion.

[4]  P. Tomasulo,et al.  Triggers for switching from minipool testing by nucleic acid technology to individual‐donation nucleic acid testing for West Nile virus: Analysis of 2003 data to inform 2004 decision making , 2004, Transfusion.

[5]  C. Southam,et al.  Induced virus infections in man by the Egypt isolates of West Nile virus. , 1954, The American journal of tropical medicine and hygiene.

[6]  R. Lanciotti,et al.  Transmission of West Nile virus through blood transfusion in the United States in 2002. , 2003, The New England journal of medicine.

[7]  Michael Engle,et al.  A Critical Role for Induced IgM in the Protection against West Nile Virus Infection , 2003, The Journal of experimental medicine.

[8]  Sally Caglioti,et al.  Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. , 2004, The New England journal of medicine.

[9]  J. Wong,et al.  Cost‐effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States , 2004, Vox sanguinis.

[10]  L. Mimms,et al.  Highly Sensitive Multiplex Assay for Detection of Human Immunodeficiency Virus Type 1 and Hepatitis C Virus RNA , 2002, Journal of Clinical Microbiology.

[11]  S. Kleinman,et al.  Transfusion transmission of West Nile virus: a merging of historical and contemporary perspectives , 2003, Transfusion.

[12]  M. Drebot,et al.  Analytical and clinical sensitivity of West Nile virus RNA screening and supplemental assays available in 2003 , 2005, Transfusion.

[13]  S. Krugman,et al.  Infectious hepatitis: detection of virus during the incubation period and in clinically inapparent infection. , 1959, The New England journal of medicine.

[14]  A. Barrett,et al.  Experimental infection of rhesus macaques with West Nile virus: level and duration of viremia and kinetics of the antibody response after infection. , 2004, The Journal of infectious diseases.

[15]  R. Dodd Emerging infections, transfusion safety, and epidemiology. , 2003, The New England journal of medicine.

[16]  W. Hogrefe,et al.  Detection of West Nile Virus (WNV)-Specific Immunoglobulin M in a Reference Laboratory Setting during the 2002 WNV Season in the United States , 2003, Clinical Diagnostic Laboratory Immunology.

[17]  B. Turnbull The Empirical Distribution Function with Arbitrarily Grouped, Censored, and Truncated Data , 1976 .